Hurlstone D P, Sanders D S, McAlindon M E, Thomson M, Cross S S
Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield, UK.
Endoscopy. 2006 Dec;38(12):1213-7. doi: 10.1055/s-2006-944732.
Colonoscopy with mucosal biopsy is currently considered to be the "gold standard" investigation for the evaluation of disease activity and disease extent in ulcerative colitis. Conventional colonoscopic criteria are inadequate for assessing disease extent and for predicting clinical relapse, however. Histopathological markers of relapse, such as microscopic crypt abscess formation and mucin depletion cannot be identified using conventional endoscopy. The aim of this study was to evaluate the efficacy of high-magnification chromoscopic colonoscopy for the in vivo assessment of histopathological inflammation and disease extent using standardised endoscopic and histopathological criteria.
Total colonoscopy using the Olympus CF240Z magnifying colonoscope was performed prospectively in 325 consecutive patients with a known diagnosis of ulcerative colitis. A "biphasic" examination of all five colonic segments and the rectum was performed with conventional endoscopy followed by magnification imaging and biopsy. Disease activity was documented using Baron's classification, modified Saitoh criteria for magnification imaging, and Matts' histopathological grading.
A total of 1800 images from 300 patients were analyzed (25 patients were excluded). The kappa coefficients of agreement between Saitoh's magnification criteria grades 1/2, 3/4, and 5/6 and Matts' histopathological grades 1/2, 3a/b, and 4/5 were 0.96, 0.62, and 0.51, respectively. Mild, moderate, and severe histopathological disease (Matts' grades 1/2, 3a - 4, and 5) were represented more accurately using Saitoh's criteria than by conventional Baron scores for all clinical parameters ( R = 0.976; P < 0.001). Magnification imaging was significantly better than conventional colonoscopy for predicting disease extent in vivo ( P < 0.0001).
This is the largest prospective study and the only Western group to report on this application of magnification imaging. High-magnification imaging provides a sensitive and specific in vivo "virtual biopsy" in ulcerative colitis and so an instant biomarker for disease relapse, while accurately predicting disease extent. High-accuracy optical biopsy can limit the number of biopsies required, with significant cost savings for pathology services.
目前,结肠镜检查及黏膜活检被视为评估溃疡性结肠炎疾病活动度和疾病范围的“金标准”检查方法。然而,传统的结肠镜检查标准在评估疾病范围和预测临床复发方面并不充分。复发的组织病理学标志物,如显微镜下隐窝脓肿形成和黏液缺失,无法通过传统内镜检查识别。本研究的目的是使用标准化的内镜和组织病理学标准,评估高倍放大染色结肠镜检查在体内评估组织病理学炎症和疾病范围的疗效。
前瞻性地对325例已知诊断为溃疡性结肠炎的连续患者使用奥林巴斯CF240Z放大结肠镜进行全结肠镜检查。对所有五个结肠段和直肠进行“双相”检查,先进行传统内镜检查,然后进行放大成像和活检。使用巴伦分类法、改良的斋藤放大成像标准和马茨组织病理学分级记录疾病活动度。
共分析了300例患者的1800张图像(排除25例患者)。斋藤放大标准1/2级、3/4级和5/6级与马茨组织病理学分级1/2级、3a/b级和4/5级之间的一致性kappa系数分别为0.96、0.62和0.51。对于所有临床参数,使用斋藤标准比传统巴伦评分更准确地代表轻度、中度和重度组织病理学疾病(马茨分级1/2级、3a - 4级和5级)(R = 0.976;P < 0.001)。放大成像在体内预测疾病范围方面明显优于传统结肠镜检查(P < 0.0001)。
这是最大的前瞻性研究,也是唯一报道这种放大成像应用的西方研究组。高倍放大成像在溃疡性结肠炎中提供了一种敏感且特异的体内“虚拟活检”,因此是疾病复发的即时生物标志物,同时能准确预测疾病范围。高精度光学活检可以减少所需活检的数量,为病理服务节省大量成本。